Research Article
Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
Table 4
Treatments for glioblastoma administered to 60 patients who received bevacizumab therapy.
| Bevacizumab treatment sub-groups (number of subjects) | Period when treatment for glioblastoma was received | Treatment received for glioblastoma | Surgical resection | Any radiotherapy | Temozolomide | Bevacizumab | Other chemotherapy | n (%) | n (%) | n (%) | n (%) | n (%) |
| Bevacizumab received before tumor recurrence (n = 10) | At diagnosis | 9 (90.0) | 10 (100.0) | 10 (100.0) | 10 (100.0) | 2 (20.0) | At first recurrence | 2 (20.0) | 0 (0.0) | 0 (0.0) | 2 (20.0) | 3 (30.0) |
| Bevacizumab received at first tumor recurrence (n = 43) | At diagnosis | 29 (67.4) | 43 (100.0) | 43 (100.0) | 0 (0.0) | 0 (0.0) | At first recurrence | 0 (0.0) | 2 (4.7) | 9 (20.9) | 43 (100.0) | 19 (44.2) |
| Bevacizumab received at second tumor recurrence (n = 7) | At diagnosis | 7 (100.0) | 6 (85.7) | 5 (71.4) | 0 (0.0) | 2 (28.6) | At first recurrence | 7 (100.0) | 3 (42.9) | 6 (85.7) | 0 (0.0) | 1 (14.3) | At second recurrence | 0 (0.0) | 1 (14.3) | 0 (0.0) | 7 (100.0) | 5 (71.4) |
|
|